-
- Tsukahara Fujiko
- Department of Pharmacology, Tokyo Women's Medical University School of Medicine
-
- Maru Yoshiro
- Department of Pharmacology, Tokyo Women's Medical University School of Medicine
この論文をさがす
抄録
<p>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019. It has been rapidly spreading worldwide ever since. The majority of COVID-19 infections are asymptomatic or mildly symptomatic. However, old age or comorbidities can result in a cytokine storm, which eventually leads to death. To date, no drug has been clinically proven effective to treat COVID-19, and development of effective drugs against SARS-CoV-2 is urgently required. Several drugs used in treating other diseases are being evaluated. Clinical trials on many new antiviral drugs and vaccine candidates are also rapidly ongoing. In this review, we summarized the currently used drugs and newly developed vaccines for the treatment of COVID-19.</p><p>This is a secondary publication of "COVID-19 Pandemic: Drug Development and Drug Treatment" published in the Journal of Tokyo Women's Medical University (in Japanese) 91 (1): 19-28, 2021.</p>
収録刊行物
-
- Tokyo Women's Medical University Journal
-
Tokyo Women's Medical University Journal 5 (0), 19-28, 2021-12-20
東京女子医科大学学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390853423037342720
-
- NII論文ID
- 130008131520
-
- ISSN
- 24326186
-
- HANDLE
- 10470/00033115
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- IRDB
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可